deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT04659863

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia (ORION-13)

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)

Sponsor: Novartis Pharmaceuticals

Updated 24 times since 2021 Last updated: Dec 18, 2025 Started: Feb 16, 2021 Primary completion: Oct 30, 2023 Completion: Nov 18, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04659863, this PHASE3 trial focuses on Familial Hypercholesterolemia - Homozygous and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 24 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Feb 2025 · 4 months · monthly snapshot~Feb 2025 – ~Jun 2025 · 4 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

24 versions recorded
  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Nov 2025 — Feb 2026 [monthly]

    Completed PHASE3

  3. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  4. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE3

  5. Feb 2025 — Jun 2025 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

Show 19 earlier versions
  1. Oct 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Aug 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  10. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  11. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  12. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  13. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  14. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  15. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  16. Nov 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  17. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  18. Apr 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  19. Jan 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .